Sustained HBsAg Clearance in HBeAg-Negative Hepatitis B Patients

203 HBeAg-negative hepatitis B patients with low baseline HBsAg were followed for a median of 96 weeks after Peg-IFNα-2b therapy. The study, authored by Chaojing Wen, identifies end-of-treatment HBsAb levels and consolidation therapy duration as key predictors of sustained HBsAg clearance. It was last updated in May 2026.

Use Cases

• Predicting long-term HBsAg clearance based on end-of-treatment HBsAb levels.
• Analyzing the impact of consolidation therapy duration on sustained treatment response.
• Identifying risk factors for HBsAg reversion in a specific patient population.
• Validating 96 weeks as a key follow-up time point for monitoring treatment success.

Strengths

• 203 patient records provide a substantial cohort for analysis.
• Median follow-up duration of 96 weeks with a defined range (72-120 weeks) offers longitudinal data.
• Specific predictive thresholds identified, such as EOT HBsAb >1000 IU/mL correlating with 100% sustained clearance.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 16.7 KB file size suggests a very limited data scope, likely summary statistics only.

Provenance

Source

figshare

Collection Method

Retrospective study analyzing patient records.

Time Range

Follow-up period median 96 weeks (range 72-120 weeks).

Freshness

Last updated 2026-05-20 10:43:29; freshness should be verified.